Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B
Fierce Pharma
Thu, 01/13/22 - 11:00 am
Tags:
AbbVie, Rinvoq, Skyrizi, JPMHC 2022
AbbVie seeks approval for upadacitinib to treat nr-axSpA
Pharmaceutical Business Review
Mon, 01/10/22 - 11:29 am
Tags:
AbbVie, FDA, EMA, upadacatinib, nr-axSpA, non-radiographic axial spondyloarthritis
FDA grants breakthrough designation to AbbVie’s Teliso-V for NSCLC treatment
Pharmaceutical Business Review
Wed, 01/5/22 - 10:33 am
Tags:
FDA, AbbVie, Teliso-V, telisotuzumab vedotin, non-small cell lung cancer
10 clinical trials to watch in the first half of 2022
BioPharma Dive
Mon, 01/3/22 - 10:46 am
Tags:
clinical trials, Pfizer, Arena Pharmaceuticals, etrasimod, Sanofi, GSK, vaccines, COVID-19, Roche, gantenerumab, AbbVie, Gilead Sciences, Trodelvy, Karuna Therapeutics, KarXT, Intercept Pharma, obeticholic acid, Allogene, ALLO-501a
Could This FDA Approval Create a Blockbuster Drug for AbbVie?
Motley Fool
Sun, 01/2/22 - 11:36 pm
Tags:
AbbVie, Rinvoq, FDA, psoriatic arthritis
Teva suffers trial loss in New York's landmark opioid case
Fierce Pharma
Thu, 12/30/21 - 08:03 pm
Tags:
Teva Pharmaceutical, AbbVie, JNJ, New York, legal, opioids, opioid crisis
What AbbVie's Recent Drug News Means for Shareholders
Motley Fool
Tue, 12/28/21 - 10:57 am
Tags:
AbbVie, Skyrizi, Crohn’s disease, Europe
What to Make of the FDA's Latest Warning to AbbVie and Pfizer
Motley Fool
Sat, 12/18/21 - 10:56 pm
Tags:
FDA, AbbVie, Pfizer, Rinvoq, Xeljanz, JAK inhibitors
Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial
Endpoints
Wed, 12/15/21 - 11:49 pm
Tags:
Idera Pharmaceuticals, AbbVie, melanoma, clinical trials, tilsotolimod
Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change
Endpoints
Wed, 12/15/21 - 10:52 am
Tags:
Pfizer, AbbVie, Xeljanz, Rinvoq, FDA, JAK inhibitors
AbbVie prices first presbyopia drug Vuity at $80 per month
Pharmaforum
Fri, 12/10/21 - 10:48 am
Tags:
AbbVie, Vuity, presbyopia
AbbVie settles New York opioid case as trial winds down
Reuters
Wed, 12/8/21 - 11:50 pm
Tags:
AbbVie, opioids, opioid addiction, New York, legal
Former Scripps and Humira Leader Richard Lerner Passes Away
BioSpace
Tue, 12/7/21 - 11:39 pm
Tags:
Richard Lerner, Scripps Research Institute, AbbVie, Humira
Alvotech, battling AbbVie over its Humira biosim, raises $450M and tees up Nasdaq debut
Fierce Pharma
Tue, 12/7/21 - 11:07 am
Tags:
Alvotech, SPACs, AbbVie, Humira
AbbVie's Rinvoq notches Crohn's disease win amid classwide JAK safety concerns
Fierce Pharma
Mon, 12/6/21 - 11:45 pm
Tags:
AbbVie, Rinvoq, Crohn’s disease
AbbVie seeks EMA approval for risankizumab (Skyrizi) to treat moderate to severe Crohn’s disease
Pharmaceutical Business Review
Wed, 12/1/21 - 10:15 am
Tags:
AbbVie, Europe, EMA, Skyrizi, Crohn’s disease
Neuro drugs dumped by AbbVie are now heading to Neurocrine for $100M up front
MedCity News
Tue, 11/23/21 - 09:40 am
Tags:
AbbVie, Neurocrine, neurological disorders
ICER: Unsubstantiated drug price increases cost US $1.67B in 2020, but overall net increases lower than years past
Endpoints
Tue, 11/16/21 - 10:35 am
Tags:
ICER, drug pricing, Humira, AbbVie
AbbVie, University of Chicago extend oncology research collaboration
Pharmaceutical Business Review
Sat, 11/13/21 - 09:52 pm
Tags:
AbbVie, University of Chicago, R&D, oncology
ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa fleshes out competitive leukemia data again
Fierce Biotech
Thu, 11/4/21 - 10:27 am
Tags:
BeiGene, Brukinsa, leukemia, clinical trials, AbbVie, JNJ, Imbruvica

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.